EQUILLIUM, INC. (EQ) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $281.84M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $381.00K; Retained Earnings (Accumulated Deficit)USD $-226.21M.
- 2026-03-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $280.63M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $370.00K; Retained Earnings (Accumulated Deficit)USD $-221.52M.
- 2025-12-31: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $244.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $363.00K; Retained Earnings (Accumulated Deficit)USD $-216.21M.
- 2025-09-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $243.09M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $270.00K; Retained Earnings (Accumulated Deficit)USD $-212.43M.
EQUILLIUM, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Split USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.00K | $281.84M | $381.00K | $-226.21M | $56.02M | 3 month · $1.09M | (m) | (m) | (m) |
| 2026-03-31 | $5.00K | $280.63M | $370.00K | $-221.52M | $59.49M | 3 month · $930.00K | (m) | (m) | (m) |
| 2025-12-31 | $5.00K | $244.43M | $363.00K | $-216.21M | $28.60M | 12 month · $2.32M | (m) | (m) | (m) |
| 2025-09-30 | $5.00K | $243.09M | $270.00K | $-212.43M | $30.94M | 3 month · $401.00K | (m) | (m) | (m) |
| 2025-06-30 | $3.00K | $212.87M | $385.00K | $-208.20M | $5.06M | 3 month · $563.00K | (m) | (m) | (m) |
| 2025-03-31 | $3.00K | $212.31M | $731.00K | $-202.46M | $10.58M | 3 month · $621.00K | (m) | (m) | (m) |
| 2024-12-31 | $3.00K | $212.08M | $781.00K | $-193.81M | $19.06M | 12 month · $3.75M | (m) | (m) | (m) |
| 2024-09-30 | $3.00K | $211.19M | $-3.00K | $-188.01M | $23.18M | 3 month · $1.00M | (m) | (m) | (m) |
| 2024-06-30 | $3.00K | $210.19M | $251.00K | $-188.01M | $22.43M | 3 month · $952.00K | (m) | (m) | (m) |
| 2024-03-31 | $3.00K | $209.14M | $423.00K | $-188.47M | $21.09M | 3 month · $972.00K | (m) | (m) | (m) |
| 2023-12-31 | $3.00K | $208.17M | $140.00K | $-185.74M | $22.57M | 12 month · $4.00M | (m) | (m) | (m) |
| 2023-09-30 | $3.00K | $207.04M | $458.00K | $-183.40M | $24.11M | 3 month · $979.00K | (m) | (m) | (m) |
| 2023-06-30 | $3.00K | $206.33M | $340.00K | $-179.69M | $26.98M | 3 month · $934.00K | (m) | (m) | (m) |
| 2023-03-31 | $3.00K | $205.31M | $305.00K | $-176.34M | $29.27M | 3 month · $1.04M | (m) | (m) | (m) |
| 2022-12-31 | $3.00K | $204.27M | $76.00K | $-172.41M | $31.94M | 12 month · $4.84M | 12 month · $53.00K | (m) | (m) |
| 2022-09-30 | $3.00K | $203.14M | $193.00K | $-175.18M | $28.16M | 3 month · $1.19M | 3 month · $17.00K | (m) | (m) |
| 2022-06-30 | $3.00K | $201.94M | $-149.00K | $-161.52M | $40.27M | 3 month · $1.30M | 3 month · $18.00K | (m) | (m) |
| 2022-03-31 | $3.00K | $200.47M | $-454.00K | $-147.39M | $52.63M | 3 month · $1.30M | 3 month · $18.00K | (m) | (m) |
| 2021-12-31 | $2.00K | $176.62M | $-138.00K | $-109.98M | $66.50M | 12 month · $4.41M | 12 month · $73.00K | (m) | (m) |
| 2021-09-30 | $2.00K | $175.22M | $-66.00K | $-99.36M | $75.80M | 3 month · $1.15M | 3 month · $18.00K | (m) | (m) |
| 2021-06-30 | $2.00K | $174.05M | $-209.00K | $-89.07M | $84.77M | 3 month · $1.06M | 3 month · $18.00K | (m) | (m) |
| 2021-03-31 | $2.00K | $172.05M | $-255.00K | $-79.92M | $91.88M | 3 month · $1.04M | 3 month · $18.00K | (m) | (m) |
| 2020-12-31 | $2.00K | $141.07M | $-297.00K | $-70.92M | $69.85M | 12 month · $3.82M | 12 month · $73.00K | (m) | (m) |
| 2020-09-30 | $2.00K | $140.16M | $-30.00K | $-62.01M | $78.13M | 3 month · $847.00K | 3 month · $18.00K | (m) | (m) |
| 2020-06-30 | $1.00K | $86.28M | $97.00K | $-55.41M | $30.97M | 3 month · $1.35M | 3 month · $18.00K | (m) | (m) |
| 2020-03-31 | $1.00K | $84.82M | $474.00K | $-48.95M | $36.35M | 3 month · $787.00K | 3 month · $18.00K | (m) | (m) |
| 2019-12-31 | $1.00K | $82.94M | $21.00K | $-41.11M | $41.85M | 12 month · $2.25M | 12 month · $74.00K | (m) | 12 month · $266.00K |
| 2019-09-30 | $1.00K | $82.42M | $80.00K | $-33.55M | $48.96M | 3 month · $633.00K | 3 month · $18.00K | (m) | 3 month · $266.00K |
| 2019-06-30 | $1.00K | $81.51M | $87.00K | $-27.53M | $54.06M | 3 month · $581.00K | 3 month · $19.00K | (m) | (m) |
| 2019-03-31 | $1.00K | $80.91M | $49.00K | $-21.46M | $59.49M | 3 month · $446.00K | 3 month · $19.00K | (m) | (m) |
| 2018-12-31 | $1.00K | $80.44M | $5.00K | $-15.51M | $64.94M | 12 month · $442.00K | 12 month · $18.00K | 12 month · $197.00 | (m) |
| 2018-09-30 | $166.00 | $141.53K | (m) | $-10.52M | $-10.38M | 3 month · $131.00K | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-5.59M | 3 month · $1.00K | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-3.83M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $124.00 | $9.66K | (m) | $-2.26M | $-2.25M | (m) | (m) | (m) | (m) |
| 2017-03-15 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |